-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BTKCNCG7JDkndalwbh3mQe/qUSyn+pqenH1/B8mhjK94ny8jtp7TEpZ4fGEFShih RsWXuOZWzEI2d3++flpC/A== 0001209191-10-051878.txt : 20101027 0001209191-10-051878.hdr.sgml : 20101027 20101027173919 ACCESSION NUMBER: 0001209191-10-051878 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101027 FILED AS OF DATE: 20101027 DATE AS OF CHANGE: 20101027 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001338042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202960116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1140 ROUTE 22 EAST, SUITE 304 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: (908) 704-1300 MAIL ADDRESS: STREET 1: 1140 ROUTE 22 EAST, SUITE 304 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc DATE OF NAME CHANGE: 20050906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Advent Healthcare & Life Sciences III-A Limited Partnership CENTRAL INDEX KEY: 0001402736 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34921 FILM NUMBER: 101145717 BUSINESS ADDRESS: STREET 1: C/O ADVENT INTERNATIONAL CORPORATION STREET 2: 75 STATE STREET, 29TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 617-951-9400 MAIL ADDRESS: STREET 1: C/O ADVENT INTERNATIONAL CORPORATION STREET 2: 75 STATE STREET, 29TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2010-10-27 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001402736 Advent Healthcare & Life Sciences III-A Limited Partnership C/O ADVENT INTERNATIONAL CORPORATION 75 STATE STREET, 29TH FLOOR BOSTON MA 02109 0 0 0 1 Member of Group > 10% Common Stock 2454 D Common Stock 2010-10-27 4 C 0 743068 A 745522 D Common Stock 2010-10-27 4 C 0 259613 A 1005135 D Common Stock 2010-10-27 4 C 0 478852 7.60 A 1483987 D Common Stock 2010-10-27 4 P 0 154790 9.50 A 1638777 D Series A Convertible Preferred Stock 0.00 2010-10-27 4 C 0 1920018 0.00 D Common Stock 743068 0 D Series B Convertible Preferred Stock 0.00 2010-10-27 4 C 0 425403 0.00 D Common Stock 259613 0 D Senior Subordinated Convertible Promissory Notes 7.60 2010-10-27 4 C 0 3639296.57 0.00 D 2011-12-31 Common Stock 478852 0.00 D Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares") and each share of the Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, immediately converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. The Series A Shares converted on a 1-for-0.38701117412 basis and the Series B Shares converted on a 1-for-0.61027657931 basis. The Series A Shares and the Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date. Shares acquired upon the closing of the Issuer's initial public offering at the initial public offering price of $9.50 per share. The outstanding principal and accrued and unpaid interest on these senior subordinated convertible promissory notes (the "Convertible Notes") automatically converted into shares of common stock upon the closing of the Issuer's initial public offering, at $7.60 per share, 80% of the Issuer's initial public offering price per share. /s/ Jarlyth H. Gibson, Compliance Officer 2010-10-27 -----END PRIVACY-ENHANCED MESSAGE-----